Basic Information
| RNALocate ID: | RLID:11001847 |
| RNA Symbol: | hsa-miR-9-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-9 |
| RNA ID: | miRBase:MIMAT0000441 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20615901 |
| Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
| Method: | Microarray|RT-PCR |
|
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001806 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001807 | Mitochondrion | Cell line (HEK-293) | 22984580 |
| RLID:01001808 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:11001848 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11001849 | Exosome | Brain tissue | 23382797 |
| RLID:11001850 | Exosome | Plasma | 23663360 |
| RLID:11001851 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001852 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11001853 | Microvesicle | Cerebrospinal fluid | 24797360 |
| RLID-D:11000089 | Exosome | Blood|Chronic lymphocytic leukemia cells|Tongue tissue | |
| RLID-D:11000369 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-9-5p | Disease of metabolism | MNDR-E-MI-72441 |
| MNDR | hsa-miR-9-5p | Splenic marginal zone lymphoma | MNDR-E-MI-72442 |
| MNDR | hsa-miR-9-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-72443 |
| MNDR | hsa-miR-9-5p | Oral squamous cell carcinoma | MNDR-E-MI-72444 |
| MNDR | hsa-miR-9-5p | Large cell neuroendocrine cancer | MNDR-E-MI-72445 |
| MNDR | hsa-miR-9-5p | Follicular lymphoma | MNDR-E-MI-72446 |
| MNDR | hsa-miR-9-5p | Medulloblastoma | MNDR-E-MI-72447 |
| MNDR | hsa-miR-9-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-72448 |
| MNDR | hsa-miR-9-5p | Lymphoma | MNDR-E-MI-72449 |
| MNDR | hsa-miR-9-5p | Lymphoma non-hodgkin | MNDR-E-MI-72450 |
| MNDR | hsa-miR-9-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-72451 |
| MNDR | hsa-miR-9-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-72452 |
| MNDR | hsa-miR-9-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-72453 |
| MNDR | hsa-miR-9-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-72454 |
| MNDR | hsa-miR-9-5p | Her2-receptor positive breast cancer | MNDR-E-MI-72455 |
| MNDR | hsa-miR-9-5p | Triple negative breast cancer | MNDR-E-MI-72456 |
| MNDR | hsa-miR-9-5p | Anencephaly | MNDR-E-MI-72457 |
| MNDR | hsa-miR-9-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-72458 |
| MNDR | hsa-miR-9-5p | Gastric cancer | MNDR-E-MI-72459 |
| MNDR | hsa-miR-9-5p | Gastric lymphoma | MNDR-E-MI-72460 |
| MNDR | hsa-miR-9-5p | Alzheimer disease | MNDR-E-MI-72461 |
| MNDR | hsa-miR-9-5p | Intracranial aneurysm | MNDR-E-MI-72462 |
| MNDR | hsa-miR-9-5p | Urinary bladder cancer | MNDR-E-MI-72463 |
| MNDR | hsa-miR-9-5p | Sarcoma | MNDR-E-MI-72464 |
| MNDR | hsa-miR-9-5p | Dysautonomia familial | MNDR-E-MI-72465 |
| MNDR | hsa-miR-9-5p | Seizures | MNDR-E-MI-72466 |
| MNDR | hsa-miR-9-5p | Friedreich ataxia | MNDR-E-MI-72467 |
| MNDR | hsa-miR-9-5p | Huntington disease | MNDR-E-MI-72468 |
| MNDR | hsa-miR-9-5p | Chorea | MNDR-E-MI-72469 |
| MNDR | hsa-miR-9-5p | Lung cancer | MNDR-E-MI-72470 |
| MNDR | hsa-miR-9-5p | Endometrial cancer | MNDR-E-MI-72471 |
| MNDR | hsa-miR-9-5p | Down syndrome | MNDR-E-MI-72472 |
| MNDR | hsa-miR-9-5p | Parkinson disease | MNDR-E-MI-72473 |
| MNDR | hsa-miR-9-5p | Basal-like breast cancer | MNDR-E-MI-72474 |
| MNDR | hsa-miR-9-5p | Squamous cell carcinoma | MNDR-E-MI-72475 |
| MNDR | hsa-miR-9-5p | Thyroid cancer | MNDR-E-MI-72476 |
| MNDR | hsa-miR-9-5p | Malignant mesothelioma | MNDR-E-MI-72477 |
| MNDR | hsa-miR-9-5p | Pancreatic cancer | MNDR-E-MI-72478 |
| MNDR | hsa-miR-9-5p | Malignant melanoma | MNDR-E-MI-72479 |
| MNDR | hsa-miR-9-5p | Colon cancer | MNDR-E-MI-72480 |
| MNDR | hsa-miR-9-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-72481 |
| MNDR | hsa-miR-9-5p | Familial ovarian cancer | MNDR-E-MI-72482 |
| MNDR | hsa-miR-9-5p | Prostate adenocarcinoma | MNDR-E-MI-72483 |
| MNDR | hsa-miR-9-5p | Laryngeal squamous cell carcinoma | MNDR-E-MI-72484 |
| MNDR | hsa-miR-9-5p | Carcinoma ductal breast | MNDR-E-MI-72485 |
| MNDR | hsa-miR-9-5p | Invasive ductal carcinoma | MNDR-E-MI-72486 |
| MNDR | hsa-miR-9-5p | Glioblastoma | MNDR-E-MI-72487 |
| MNDR | hsa-miR-9-5p | Glioblastoma multiforme somatic | MNDR-E-MI-72488 |
| MNDR | hsa-miR-9-5p | Glioma | MNDR-E-MI-72489 |
| MNDR | hsa-miR-9-5p | Oligodendroglioma | MNDR-E-MI-72490 |
| MNDR | hsa-miR-9-5p | Neurilemmoma | MNDR-E-MI-72491 |
| MNDR | hsa-miR-9-5p | Central nervous system lymphoma | MNDR-E-MI-72492 |
| MNDR | hsa-miR-9-5p | Rhabdomyosarcoma | MNDR-E-MI-72493 |
| MNDR | hsa-miR-9-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-72494 |
| MNDR | hsa-miR-9-5p | Epilepsy temporal lobe | MNDR-E-MI-72495 |
| MNDR | hsa-miR-9-5p | Osteosarcoma | MNDR-E-MI-72496 |
| MNDR | hsa-miR-9-5p | Uterus cancer | MNDR-E-MI-72497 |
| MNDR | hsa-miR-9-5p | Melas syndrome | MNDR-E-MI-72498 |
| MNDR | hsa-miR-9-5p | Cervical adenocarcinoma | MNDR-E-MI-72499 |
| MNDR | hsa-miR-9-5p | Gastric adenocarcinoma | MNDR-E-MI-72500 |
| MNDR | hsa-miR-9-5p | Cervical squamous cell carcinoma | MNDR-E-MI-72501 |
| MNDR | hsa-miR-9-5p | Pituitary adenoma | MNDR-E-MI-72502 |
| MNDR | hsa-miR-9-5p | Lung squamous cell carcinoma | MNDR-E-MI-72503 |
| MNDR | hsa-miR-9-5p | Carcinoma lung non-small-cell | MNDR-E-MI-72504 |
| MNDR | hsa-miR-9-5p | Lung adenocarcinoma | MNDR-E-MI-72505 |
| MNDR | hsa-miR-9-5p | Thyroid carcinoma | MNDR-E-MI-72506 |
| MNDR | hsa-miR-9-5p | Papillary thyroid carcinoma | MNDR-E-MI-72507 |
| MNDR | hsa-miR-9-5p | Brain stem cancer | MNDR-E-MI-72508 |
| MNDR | hsa-miR-9-5p | Cervical cancer | MNDR-E-MI-72509 |
| MNDR | hsa-miR-9-5p | Carcinoma renal cell | MNDR-E-MI-72510 |
| MNDR | hsa-miR-9-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-72511 |
| MNDR | hsa-miR-9-5p | Renal clear cell carcinoma | MNDR-E-MI-72512 |
| MNDR | hsa-miR-9-5p | Large cell carcinoma | MNDR-E-MI-72513 |
| MNDR | hsa-miR-9-5p | Cholangiocarcinoma | MNDR-E-MI-72514 |
| MNDR | hsa-miR-9-5p | Esophageal cancer | MNDR-E-MI-72515 |
| MNDR | hsa-miR-9-5p | Lung small cell carcinoma | MNDR-E-MI-72516 |
| MNDR | hsa-miR-9-5p | Schizophrenia | MNDR-E-MI-72517 |
| MNDR | hsa-miR-9-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-72518 |
| MNDR | hsa-miR-9-5p | Heart failure | MNDR-E-MI-72519 |
| MNDR | hsa-miR-9-5p | Uveal melanoma | MNDR-E-MI-72520 |
| MNDR | hsa-miR-9-5p | Breast invasive carcinoma | MNDR-E-MI-72521 |
| MNDR | hsa-miR-9-5p | Progressive supranuclear palsy | MNDR-E-MI-72522 |
| MNDR | hsa-miR-9-5p | Hepatocellular carcinoma | MNDR-E-MI-72523 |
| MNDR | hsa-miR-9-5p | Embryonal tumors | MNDR-E-MI-72524 |
| MNDR | hsa-miR-9-5p | Familiar ovarian carcinoma | MNDR-E-MI-72525 |
| MNDR | hsa-miR-9-5p | B-cell lymphoma | MNDR-E-MI-72526 |
| MNDR | hsa-miR-9-5p | T-cell leukemia | MNDR-E-MI-72527 |
| MNDR | hsa-miR-9-5p | Neuroblastoma | MNDR-E-MI-72528 |
| MNDR | hsa-miR-9-5p | Hodgkin lymphoma | MNDR-E-MI-72529 |
| MNDR | hsa-miR-9-5p | Burkitt lymphoma | MNDR-E-MI-72530 |
| MNDR | hsa-miR-9-5p | Mouth neoplasms | MNDR-E-MI-72531 |
| MNDR | hsa-miR-9-5p | Acute myelocytic leukemia | MNDR-E-MI-72532 |
| MNDR | hsa-miR-9-5p | Colorectal cancer | MNDR-E-MI-72533 |
| MNDR | hsa-miR-9-5p | Nasopharynx carcinoma | MNDR-E-MI-72534 |
| MNDR | hsa-miR-9-5p | Multiple myeloma | MNDR-E-MI-72535 |
| MNDR | hsa-miR-9-5p | Acute lymphocytic leukemia | MNDR-E-MI-72536 |
| MNDR | hsa-miR-9-5p | Ovarian epithelial cancer | MNDR-E-MI-72537 |
| MNDR | hsa-miR-9-5p | Uterine cervical neoplasms | MNDR-E-MI-72538 |
| MNDR | hsa-miR-9-5p | Ependymoma | MNDR-E-MI-72539 |
| MNDR | hsa-miR-9-5p | Prostatic neoplasms | MNDR-E-MI-72540 |
| MNDR | hsa-miR-9-5p | Aids dementia complex | MNDR-E-MI-72541 |
| MNDR | hsa-miR-9-5p | Epstein-barr virus infections | MNDR-E-MI-72542 |
| MNDR | hsa-miR-9-5p | Gait ataxia | MNDR-E-MI-72543 |
| MNDR | hsa-miR-9-5p | Stroke lacunar | MNDR-E-MI-72544 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCC1 | Homo sapiens | RR00023333 |
TOP